Congenital toxoplasmosis: potential outcomes and therapeutic challenges - a complex case report of the newborn with treatment-resistant manifestations
DOI:
https://doi.org/10.12775/JEHS.2024.54.014Keywords
congenital toxoplasmosis, toxoplasma gondii, hydrocephalus, seizuresAbstract
Introduction and purpose
Toxoplasmosis, a prevalent parasitic infection caused by Toxoplasma gondii, impacts approximately one-third of the global population. Among congenital infections, Congenital Toxoplasmosis (CT) ranks second only to CMV infection in neonates. The severity of fetal and neonatal clinical manifestations depends on factors such as gestational age during infection, parasite load, infectious strain virulence, and maternal immune status. The organogenesis stage in the second trimester is identified as the critical period (10th-24th gestational weeks). Fetal CT may present with ultrasound-detected abnormalities, including intracranial calcifications, microcephaly, hydrocephalus, ascites, hepatosplenomegaly or severe intrauterine growth restriction. Even in the absence of symptoms at birth, CT can lead to long-term consequences such as hydrocephalus, seizures, and cognitive, auditory, and visual impairments.
The aim of this study is to present a clinical case of a patient with CT infection complicated by treatment-resistant hydrocephalus and neurological symptoms, including muscle tone disturbances and seizures.
Conclusion
The significance of screening tests cannot be overstated, as early intervention is crucial to prevent enduring complications. Routine counseling for pregnant women is imperative to raise awareness about Toxoplasma gondii infection, empowering them to adopt necessary preventive measures. Additionally, further research is warranted to assess the efficacy of diverse treatment protocols, the risk of adverse effects, and the effectiveness of emerging therapeutic agents.
References
Ahmed M, Sood A, Gupta J. Toxoplasmosis in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2020 Dec;255:44-50. doi: 10.1016/j.ejogrb.2020.10.003. Epub 2020 Oct 8. PMID: 33075679
Mandelbrot L. Congenital toxoplasmosis: What is the evidence for chemoprophylaxis to prevent fetal infection? Prenat Diagn. 2020 Dec;40(13):1693-1702. doi: 10.1002/pd.5758. Epub 2020 Jun 29. PMID: 32453454
Kota AS, Shabbir N. Congenital Toxoplasmosis. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 31424812
Deganich M, Boudreaux C, Benmerzouga I. Toxoplasmosis Infection during Pregnancy. Trop Med Infect Dis. 2022 Dec 21;8(1):3. doi: 10.3390/tropicalmed8010003. PMID: 36668910; PMCID: PMC9862191
Peyron F, L'ollivier C, Mandelbrot L, Wallon M, Piarroux R, Kieffer F, Hadjadj E, Paris L, Garcia-Meric P. Maternal and Congenital Toxoplasmosis: Diagnosis and Treatment Recommendations of a French Multidisciplinary Working Group. Pathogens. 2019 Feb 18;8(1):24. doi: 10.3390/pathogens8010024. PMID: 30781652; PMCID: PMC6470622
Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008 Aug 15;47(4):554-66. doi: 10.1086/590149. PMID: 18624630
Niezgoda, Anna and Anna Dobrzańska. “Congenital toxoplasmosis – diagnosis and treatment./Toksoplazmoza wrodzona – rozpoznawanie i leczenie” (2008).
http://esccap.pl/datastore/download/Toksoplazmoza-wrodzona-rozpoznawanie-i-leczenie.pdf
Garweg JG, Kieffer F, Mandelbrot L, Peyron F, Wallon M. Long-Term Outcomes in Children with Congenital Toxoplasmosis-A Systematic Review. Pathogens. 2022 Oct 15;11(10):1187. doi: 10.3390/pathogens11101187. PMID: 36297244; PMCID: PMC9610672
Khan K, Khan W. Congenital toxoplasmosis: An overview of the neurological and ocular manifestations. Parasitol Int. 2018 Dec;67(6):715-721. doi: 10.1016/j.parint.2018.07.004. Epub 2018 Jul 21. PMID: 30041005
Laurent Mandelbrot MD, François Kieffer MD, Rémi Sitta MSc, Hélène Laurichesse-Delmas MD, Norbert Winer MD, PhD, Louis Mesnard MD, Alain Berrebi MD, Gwenaëlle Le Bouar MD, Jean-Paul Bory MD, Anne-Gaëlle Cordier MD, Yves Ville MD, PhD, Franck Perrotin MD, PhD, Jean-Marie Jouannic MD, PhD, Florence Biquard MD, Claude d’Ercole MD, PhD, Véronique Houfflin-Debarge MD, PhD, Isabelle Villena MD, PhD, Rodolphe Thiébaut MD, PhD, TOXOGEST Study Group Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial American Journal of Obstetrics and Gynecology Volume 219, Issue 4, October 2018, Pages 386.e1-386.e9 https://doi.org/10.1016/j.ajog.2018.05.031
Lago EG, Endres MM, Scheeren MFDC, Fiori HH. Ocular Outcome of Brazilian Patients With Congenital Toxoplasmosis. Pediatr Infect Dis J. 2021 Jan;40(1):e21-e27. doi: 10.1097/INF.0000000000002931. PMID: 33060522
Valentini, P., Buonsenso, D., Barone, G. et al. Spiramycin/cotrimoxazole versus pyrimethamine/sulfonamide and spiramycin alone for the treatment of toxoplasmosis in pregnancy. J Perinatol 35, 90–94 (2015). https://doi.org/10.1038/jp.2014.161
Milewska-Bobula B, Lipka B, Gołąb E, Dębski R, Marczyńska M, Paul M, Panasiuk A, Seroczyńska M, Mazela J, Dunin-Wąsowicz D. Recommended management of Toxoplasma gondii infection in pregnant women and their children. Przegl Epidemiol. 2015;69(2):291-8, 403-10. English, Polish. PMID: 26233090
Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E. Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving. PLoS Negl Trop Dis. 2017 Jul 10;11(7):e0005648. doi: 10.1371/journal.pntd.0005648. PMID: 28692640; PMCID: PMC5503164
Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev. 2012 Apr;25(2):264-96. doi: 10.1128/CMR.05013-11. Erratum in: Clin Microbiol Rev. 2012 Jul;25(3):583. PMID: 22491772; PMCID: PMC3346298
Kieffer F, Wallon M. Congenital toxoplasmosis. Handb Clin Neurol. 2013;112:1099-101. doi: 10.1016/B978-0-444-52910-7.00028-3. PMID: 23622316
The SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data The Lancet Volume 369, Issue 9556, 13–19 January 2007, Pages 115-122 https://doi.org/10.1016/S0140-6736(07)60072-5
Boyer KM, Holfels E, Roizen N, Swisher C, Mack D, Remington J, Withers S, Meier P, McLeod R; Toxoplasmosis Study Group. Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: Implications for prenatal management and screening. Am J Obstet Gynecol. 2005 Feb;192(2):564-71. doi: 10.1016/j.ajog.2004.07.031. PMID: 15696004
Wallon, M., Franck, J., Thulliez, P., Huissoud, C., Peyron, F., Garcia-Meric, P., Kieffer, F. Accuracy of real-time polymerase chain reaction for toxoplasma gondii in amniotic fluid (2010) Obstetrics and Gynecology, 115 (4), pp. 727-733.
DOI: 10.1097/AOG.0b013e3181d57b09
Itzhak Brook, MD, MSc; Chief Editor: Russell W Steele, MD Pediatric Toxoplasmosis Clinical Presentation Updated: Sep 20, 2019 https://emedicine.medscape.com/article/1000028-clinical?form=fpf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Emilia Kowalczyk, Sylwia Koziej, Martyna Niemczuk, Adrianna Jasiuk, Mateusz Wiekiera
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 466
Number of citations: 0